128 related articles for article (PubMed ID: 3653185)
1. Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
Baguley BC; Wilson WR
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):607-13. PubMed ID: 3653185
[TBL] [Abstract][Full Text] [Related]
2. Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice.
Baguley BC; Kernohan AR; Wilson WR
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1607-13. PubMed ID: 6688994
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells.
Baguley BC; Finlay GJ
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):205-10. PubMed ID: 3356208
[TBL] [Abstract][Full Text] [Related]
4. Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma.
Baguley BC; Grimwade CD; Kernohan AR
Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1337-41. PubMed ID: 3841068
[TBL] [Abstract][Full Text] [Related]
5. Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
Rewcastle GW; Baguley BC; Atwell GJ; Denny WA
J Med Chem; 1987 Sep; 30(9):1576-81. PubMed ID: 3625706
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells.
Ching LM; Finlay GJ; Joseph WR; Baguley BC
Eur J Cancer; 1990 Jan; 26(1):49-54. PubMed ID: 2138478
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma.
Rewcastle GW; Denny WA; Wilson WR; Baguley BC
Anticancer Drug Des; 1986 Nov; 1(3):215-22. PubMed ID: 3450294
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
Baguley BC; Denny WA; Atwell GJ; Finlay GJ; Rewcastle GW; Twigden SJ; Wilson WR
Cancer Res; 1984 Aug; 44(8):3245-51. PubMed ID: 6547635
[TBL] [Abstract][Full Text] [Related]
9. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
Schneider E; Darkin SJ; Lawson PA; Ching LM; Ralph RK; Baguley BC
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1783-90. PubMed ID: 2850193
[TBL] [Abstract][Full Text] [Related]
10. Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
Finlay GJ; Wilson WR; Baguley BC
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1695-701. PubMed ID: 2561099
[TBL] [Abstract][Full Text] [Related]
11. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Baguley BC; Holdaway KM; Fray LM
J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
13. Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.
Baguley BC; Finlay GJ
J Natl Cancer Inst; 1988 Apr; 80(3):195-9. PubMed ID: 3346911
[TBL] [Abstract][Full Text] [Related]
14. Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
Atwell GJ; Rewcastle GW; Baguley BC; Denny WA
J Med Chem; 1987 Apr; 30(4):652-8. PubMed ID: 3560159
[TBL] [Abstract][Full Text] [Related]
15. Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
Finlay GJ; Baguley BC
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):271-7. PubMed ID: 2702982
[TBL] [Abstract][Full Text] [Related]
16. Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.
Finlay GJ; Holdaway KM; Baguley BC
Cancer Chemother Pharmacol; 1994; 34(2):159-65. PubMed ID: 8194167
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
18. Amsacrine analogues with extended chromophores: DNA binding and anti-tumour activity.
Denny WA; Baguley BC
Anticancer Drug Des; 1987 Aug; 2(1):61-70. PubMed ID: 3449085
[TBL] [Abstract][Full Text] [Related]
19. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
20. Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
Denny WA; Atwell GJ; Baguley BC
J Med Chem; 1984 Mar; 27(3):363-7. PubMed ID: 6546590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
